From the Journals

H. pylori eradication cuts new gastric cancers by half

View on the News

Striking result in early gastric cancer patients

The study by Choi and colleagues suggests Helicobacter pylori eradication is effective at stopping the carcinogenic process in patients with severe chronic atrophic gastritis, an advanced precursor lesion to gastric cancer, according to Peter Malfertheiner, MD.

“It is a striking finding that H. pylori eradication may still be effective at this stage, since such therapy decreased the development of gastric cancer by 50% in this trial,” Dr. Malfertheiner wrote in an editorial.

In the randomized, placebo-controlled trial, H. pylori eradication after endoscopic removal of early stage disease effectively prevented metachronous gastric cancers (i.e., those detected on endoscopy at 1-year follow-up or thereafter) with a hazard ratio of 0.50, Dr. Malfertheiner noted.

The results confirm and strengthen previous findings by showing a significant improvement in atrophic gastritis, he added.

“In this endoscopic procedure, removal of early gastric cancer or high-grade adenoma leaves the stomach largely conserved but with the atrophic gastric mucosa remaining in a preneoplastic ‘alarm state,’ ” he noted.

However, the potential link between cancer recurrence and atrophic gastritis was not explored in this particular study report, Dr. Malfertheiner said. Thus, it is unclear whether gastric cancer recurrence was prevented specifically in the subset of patients with atrophic gastritis.

It could be that eradication of H. pylori directly arrests carcinogenic mechanisms directly by ending persistent inflammation, he speculated.

“The beneficial effect may also be mediated by an alteration in the composition of the gastric microbiota because of improvement in the grade of gastric atrophy and a return toward normal gastric acid production,” he added.

Dr. Malfertheiner is with the Clinic of Gastroenterology, Otto von Guericke University, Magdeburg, Germany. These comments are derived from his editorial (N Engl J Med. 2018 Mar 22. doi: 10.1056/NEJMe1800147). Dr. Malfertheiner reported personal fees from Allergan, Biohit, and Infai outside the submitted editorial.


 

FROM THE NEW ENGLAND JOURNAL OF MEDICINE


One nonrandomized study suggested H. pylori eradication could prevent development of subsequent cancers after endoscopic resection, according to the authors, but subsequent open-label trials were inconsistent on whether the treatment reduced cancer incidence.

Accordingly, Dr. Choi and colleagues conducted a prospective, double-blind, placebo-controlled, randomized trial of 470 patients who underwent endoscopic resection for high-grade adenoma or early gastric cancer.

Of 396 patients included in an intention-to-treat analysis, 194 were randomized to receive antibiotics for H. pylori eradication, and 202 received placebo.

Over a median follow-up of 5.9 years, new gastric cancers developed in 14 patients (7.2%) who received treatment, and in 27 patients (13.4%) who received placebo (hazard ratio, 0.50; 95% confidence interval, 0.26-0.94; P = .03).

Recommended Reading

VIDEO: Model supports endoscopic resection for some T1b esophageal adenocarcinomas
MDedge Hematology and Oncology
Colorectal cancer deaths projected for 2018
MDedge Hematology and Oncology
Exercise during chemotherapy may yield long-term physical benefits
MDedge Hematology and Oncology
Massive liver metastasis from colon adenocarcinoma causing cardiac tamponade
MDedge Hematology and Oncology
Mortality estimates put pancreatic cancer on the map
MDedge Hematology and Oncology
NASH rapidly overtaking hepatitis C as cause of liver cancer
MDedge Hematology and Oncology
New treatment options emerge for intermediate, advanced HCC
MDedge Hematology and Oncology
Colorectal cancer risk stratification enhanced by combining family history and genetic risk scores
MDedge Hematology and Oncology
MDedge Daily News: Why the barber’s chair can help hypertension
MDedge Hematology and Oncology
TACE plus radiotherapy improves outcomes in poor-prognosis hepatocellular carcinoma
MDedge Hematology and Oncology